Baseline characteristics, regimen details, immune-related AEs, day 30 and day 90 hematologic toxicities, and infection rates in the analyzed population
| Baseline characteristics . | n (range) . |
|---|---|
| Median age (range), y | 66 (41-85) |
| Median time from diagnosis (IQR), y | 5.2 (3.2-7.9) |
| Sex, female, n (%) | 28 (55) |
| Race, n (%) | |
| White | 33 (65) |
| Black | 8 (16) |
| Asian | 6 (12) |
| Mixed/other/unknown | 4 (8) |
| Performance status, n (%) | |
| ECOG 0 | 10 (20) |
| ECOG 1 | 34 (67) |
| ECOG 2 | 7 (14) |
| Creatinine clearance∗ , n (%) | |
| >60 mL/min per 1.73 m2 | 38 (75) |
| 30-60 mL/min per 1.73 m2 | 9 (18) |
| <30 mL/min per 1.73 m2 | 4 (8) |
| Multiple myeloma subtype, n (%) | |
| IgG | 38 (75) |
| IgA | 6 (12) |
| Light chain only | 7 (14) |
| Predominant light chain isotype, n (%) | |
| Kappa | 33 (65) |
| Lambda | 18 (35) |
| Disease staging, n (%) | |
| R-ISS I | 12 (24) |
| R-ISS II | 31 (61) |
| R-ISS III | 8 (16) |
| High-risk cytogenetics†, n (%) | 30 (59) |
| Extramedullary disease, n (%) | 22 (43) |
| ≥5% circulating plasma cells, n (%) | 5 (10) |
| Nonmeasurable disease, n (%) | 9 (18) |
| Prior lines of therapy, median (range) | 7 (4-17) |
| Triple-class refractory disease‡, n (%) | 48 (94) |
| Penta-refractory disease§, n (%) | 17 (33) |
| Prior HDT/ASCT, n (%) | 42 (82) |
| Prior T-cell–redirecting therapy|| n (%) | 36 (71) |
| Prior BCMA-directed therapy¶, n (%) | 36 (71) |
| Prior GPRC5D-directed therapy¶, n (%) | 1 (2) |
| Talquetamab regimen details | |
| Clinical setting of talquetamab use, n (%) | |
| Salvage therapy for RRMM | 44 (86) |
| Bridging therapy before CAR T-cell therapy | 7 (14) |
| Talquetamab dosing, n (%) | |
| 0.4 mg/kg weekly | 17 (33) |
| 0.8 mg/kg Q2W | 34 (67) |
| Median duration of treatment (IQR), wk | 17 (5-30) |
| Treatment-related AEs, all-grade and grade ≥3 | |
| Immune-related toxicities, n (%) | |
| CRS | 28 (55) |
| Grade I | 14 (27) |
| Grade II | 13 (25) |
| Grade III | 1 (2) |
| ICANS | 7 (14) |
| Grade I | 4 (8) |
| Grade II | 2 (4) |
| Grade III | 1 (2) |
| IEC-HS, n (%) | 1 (2); 1 (2) |
| Hematologic toxicities at day 30, n (%) | |
| Anemia | 19 (37); 7 (14) |
| Thrombocytopenia | 28 (55); 16 (31) |
| Neutropenia | 25 (49); 11 (22) |
| Lymphopenia | 29 (57); 19 (37) |
| Hematologic AEs at day 90 (n = 39)#, n (%) | |
| Anemia | 8 (21); 1 (3) |
| Thrombocytopenia | 9 (23); 3 (8) |
| Neutropenia | 12 (31); 1 (3) |
| Lymphopenia | 18 (46); 10 (26) |
| Infections within 90 days, n (%) | 32 (63); 19 (37) |
| Baseline characteristics . | n (range) . |
|---|---|
| Median age (range), y | 66 (41-85) |
| Median time from diagnosis (IQR), y | 5.2 (3.2-7.9) |
| Sex, female, n (%) | 28 (55) |
| Race, n (%) | |
| White | 33 (65) |
| Black | 8 (16) |
| Asian | 6 (12) |
| Mixed/other/unknown | 4 (8) |
| Performance status, n (%) | |
| ECOG 0 | 10 (20) |
| ECOG 1 | 34 (67) |
| ECOG 2 | 7 (14) |
| Creatinine clearance∗ , n (%) | |
| >60 mL/min per 1.73 m2 | 38 (75) |
| 30-60 mL/min per 1.73 m2 | 9 (18) |
| <30 mL/min per 1.73 m2 | 4 (8) |
| Multiple myeloma subtype, n (%) | |
| IgG | 38 (75) |
| IgA | 6 (12) |
| Light chain only | 7 (14) |
| Predominant light chain isotype, n (%) | |
| Kappa | 33 (65) |
| Lambda | 18 (35) |
| Disease staging, n (%) | |
| R-ISS I | 12 (24) |
| R-ISS II | 31 (61) |
| R-ISS III | 8 (16) |
| High-risk cytogenetics†, n (%) | 30 (59) |
| Extramedullary disease, n (%) | 22 (43) |
| ≥5% circulating plasma cells, n (%) | 5 (10) |
| Nonmeasurable disease, n (%) | 9 (18) |
| Prior lines of therapy, median (range) | 7 (4-17) |
| Triple-class refractory disease‡, n (%) | 48 (94) |
| Penta-refractory disease§, n (%) | 17 (33) |
| Prior HDT/ASCT, n (%) | 42 (82) |
| Prior T-cell–redirecting therapy|| n (%) | 36 (71) |
| Prior BCMA-directed therapy¶, n (%) | 36 (71) |
| Prior GPRC5D-directed therapy¶, n (%) | 1 (2) |
| Talquetamab regimen details | |
| Clinical setting of talquetamab use, n (%) | |
| Salvage therapy for RRMM | 44 (86) |
| Bridging therapy before CAR T-cell therapy | 7 (14) |
| Talquetamab dosing, n (%) | |
| 0.4 mg/kg weekly | 17 (33) |
| 0.8 mg/kg Q2W | 34 (67) |
| Median duration of treatment (IQR), wk | 17 (5-30) |
| Treatment-related AEs, all-grade and grade ≥3 | |
| Immune-related toxicities, n (%) | |
| CRS | 28 (55) |
| Grade I | 14 (27) |
| Grade II | 13 (25) |
| Grade III | 1 (2) |
| ICANS | 7 (14) |
| Grade I | 4 (8) |
| Grade II | 2 (4) |
| Grade III | 1 (2) |
| IEC-HS, n (%) | 1 (2); 1 (2) |
| Hematologic toxicities at day 30, n (%) | |
| Anemia | 19 (37); 7 (14) |
| Thrombocytopenia | 28 (55); 16 (31) |
| Neutropenia | 25 (49); 11 (22) |
| Lymphopenia | 29 (57); 19 (37) |
| Hematologic AEs at day 90 (n = 39)#, n (%) | |
| Anemia | 8 (21); 1 (3) |
| Thrombocytopenia | 9 (23); 3 (8) |
| Neutropenia | 12 (31); 1 (3) |
| Lymphopenia | 18 (46); 10 (26) |
| Infections within 90 days, n (%) | 32 (63); 19 (37) |
For categorical variables, percentages were calculated from raw counts and rounded to the nearest whole number; as a result, totals may vary slightly from 100%. A total of 51 patients were included, unless otherwise specified.
BCMA, B-cell maturation antigen; CAR-T, chimeric antigen receptor T-cell therapy; ECOG, Eastern Cooperative Oncology Group; HDT/ASCT, high-dose chemotherapy followed by autologous hematopoietic stem cell transplant; IEC-HS, immune effector cell–associated hemophagocytic lymphohistiocytosis–like syndrome; IgA, immunoglobulin A; R-ISS, Revised International Staging System.
Estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
Presence of one or more of the following cytogenetic abnormalities upon fluorescent in situ hybridization testing: t(4;14), t(14;16), and del(17p).
Failure to achieve at least a partial response or progression within 60 days of last exposure to an immunomodulatory drug, a proteasome inhibitor, and anti-CD38 monoclonal antibody.
Failure to achieve at least a partial response or progression within 60 days of last exposure to lenalidomide, pomalidomide, bortezomib, carfilzomib, and anti-CD38 monoclonal antibody.
This includes bispecific antibodies targeting BCMA (eg, teclistamab, elranatamab, or linvoseltamab) or FcRH5 (eg, cevostamab), as well as (CAR-T) targeting BCMA (eg, ide-cel or cilta-cel) or GPRC5D (eg, MCARH109).
This includes BCMA-directed bispecific antibodies (eg, teclistamab, elranatamab, or linvoseltamab), CAR T cell (eg, idecabtagene viculeucel [ide-cel] or ciltacabtagene autoleucel [cilta-cel]), or antibody-drug conjugates (eg, belantamab mafodotin).
At the 3-month time point, 12 patients had either died or started another line of therapy.